about
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancerVascular Complications of Cancer ChemotherapyMembrane transporters as mediators of Cisplatin effects and side effects.Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide.A case of chronic hypomagnesemia in a cancer survivor.Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.Testicular cancer survivorship: research strategies and recommendations.Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.Toxicity of platinum compounds.Management of oxaliplatin-induced peripheral neuropathy.Magnesium basicsBone mineral density change during adjuvant chemotherapy in pediatric osteosarcomaCetuximab therapy and symptomatic hypomagnesemia.A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatinEffect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial.Sex-related Difference in Protective Role of Aerobic Exercise against Cisplatin-induced Hepatotoxicity.Drug-induced alterations in Mg2+ homoeostasis.Magnesium and its transporters in cancer: a novel paradigm in tumour development.Systematic review: hypomagnesaemia induced by proton pump inhibition.Hypomagnesemia as a possible explanation behind episodes of severe pain in cancer patients receiving palliative care.Epilepsy in women with gynecologic malignancies.Onco-nephrology: current concepts and future perspectives.Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literature.Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.Inherited and acquired disorders of magnesium homeostasis.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta -aminoester)-graft-PEG for cancer chemotherapy.Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.Hypercalcemia associated with a malignant brenner tumor arising from a mature cystic teratoma.Time course of cisplatin-induced nephrotoxicity and hepatotoxicity.[Ischemic stroke after chemotherapy with cisplatin, etoposide and bleomycin: case report].Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer.Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone.Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
P2860
Q24197545-AD30CD25-E5E2-4245-86DD-87718CCB42FFQ26766269-55594044-BBC9-4A2C-A68C-4311BB508798Q30446860-9914BCEB-9CDA-4656-90B4-88A64B1B0289Q30890450-E2C22E29-F06A-4068-B237-0A94C1021540Q33168174-34F9E0BA-3DF9-450F-8C8B-7AD7DC59D1FDQ33645678-15B17376-A215-4965-AED5-C216B36BA335Q33895592-87CCE88B-7318-43FB-A24B-03D98D14EDBAQ34039684-D927E552-9EC2-40E0-A5A8-5D18B4F4CFB8Q34679345-217AA63A-AE4F-4B81-A480-98E56176B96EQ34748754-85406AFA-2BC8-4BA7-ACB9-648845E2C014Q35143947-8BAB96F0-00AD-460F-8C90-6F45B4FB6DE6Q35166744-B9F87E36-5C48-4AD3-B77F-A559B7D06344Q35683770-7204357C-C8D4-41DB-8B17-3B2A145E70EAQ36215768-3DEB9375-0091-46A0-8E93-0BCB9E76241CQ36232646-BB6087ED-8546-4319-812C-7027F093E6D6Q36355684-6A8CD5B5-CEB1-4681-B0AD-EECF3D104624Q36671514-F328D871-5E5E-4B5A-9F90-EC2B659DD307Q36769780-1ED8E44F-FC1A-494E-AA27-289702573A3FQ37050973-AC8682D0-EB4B-42C7-92D7-2095DE67B33BQ37992700-EB3CF0E1-E69A-4BF8-A5D4-631523D50118Q38016492-00E8491C-E1CB-4F05-A5BE-D0679F5F1899Q38023882-12112B7A-DD03-473D-B39A-41C374E6305DQ38064737-64322732-6893-48B4-9CC6-82F440A5DBABQ38205012-6D6B951C-FF3E-46AC-88F1-0010F247B885Q38382457-BA1A5589-D9CF-47C5-8A0A-75BEFF20EAFFQ38668802-B6B5CE35-D783-414D-BAE0-DCD7DDCDA17AQ38875402-FC137B9D-0649-4AAE-86B8-4030690ADC47Q38878449-F74A80B9-FA9F-4986-9D86-E70EEC203811Q38983107-56960223-F223-423D-BF60-82B8907E3AE6Q39025913-E33046F4-A53C-427E-AB51-0D955233D94DQ39229404-8CBC7811-064C-4CB9-A587-4E0FD63C17C2Q40110955-7D993382-1491-41E6-9E89-EAC27E48C475Q40309785-BA22C3F0-023D-4237-8E80-DF0820635981Q42352769-13ED5D20-B5A7-40B2-8A77-6E5C1F388019Q42361923-5EA1DA1D-0F6F-4EBB-8D36-C526AAC57ECEQ44417643-368683AD-5F06-400F-AA9D-AFEA5B9D1E6DQ44741721-04024027-867D-4BCB-A933-7E0AB55E8928Q45361894-6CF4898E-0FD8-437C-8001-844D79BA2675Q46226270-9CDDE68B-3996-422F-9CB9-AD7D421CAD9FQ47381902-19582ABD-753F-459C-A9E5-3D40E566126D
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cisplatin and hypomagnesemia.
@ast
Cisplatin and hypomagnesemia.
@en
type
label
Cisplatin and hypomagnesemia.
@ast
Cisplatin and hypomagnesemia.
@en
prefLabel
Cisplatin and hypomagnesemia.
@ast
Cisplatin and hypomagnesemia.
@en
P356
P1476
Cisplatin and hypomagnesemia.
@en
P2093
P356
10.1053/CTRV.1999.0097
P577
1999-02-01T00:00:00Z